Mortality in members of HIV-1 serodiscordant couples in Africa and implications for antiretroviral therapy initiation: Results of analyses from a multicenter randomized trial

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  de Bruyn, Guy ^a,d   Magaret, Amalia ^b,c   Baeten, Jared M ^b   Lingappa, Jairam R ^b   Ndase, Patrick ^b   Celum, Connie ^b   Wald, Anna ^b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d SANOFI PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIRETROVIRUS AGENT; PLACEBO; VIRUS RNA;

ADULT; ARTICLE; BOTSWANA; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEALTH CARE ACCESS; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; KENYA; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MIXED INFECTION; MORTALITY; MULTICENTER STUDY; NUMBERS NEEDED TO TREAT; PATIENT MONITORING; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RWANDA; SECONDARY ANALYSIS; SERODISCORDANT COUPLE; SOUTH AFRICA; TANZANIA; UGANDA; VIRUS LOAD; VIRUS TRANSMISSION; ZAMBIA;

ADULT; AFRICA; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; YOUNG ADULT;

EID: 84867897200     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-277     Document Type: Article

References (36)

1. Phillips AN, Elford J, Sabin C, Bofill M, Janossy G, Lee CA. Immunodeficiency and the risk of death in HIV infection. JAMA 1992, 268(19):2662-2666. 10.1001/jama.1992.03490190062032, 1359163.
2. Severe P, Jean Juste MA, Ambroise A, et al. Early versus Standard Antiretroviral Therapy for HIV-Infected Adults in Haiti. N Engl J Med 2010, 363(3):257-265. 10.1056/NEJMoa0910370, 20647201.
3. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009, 360(18):1815-1826. 10.1056/NEJMoa0807252, 2854555, 19339714.
4. Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009, 373(9672):1352-1363. 2670965, 19361855.
5. Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008, 197(8):1133-1144.
6. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011, 365(6):493-505. 10.1056/NEJMoa1105243, 3200068, 21767103.
7. World Health Organization World Health Organization). Rapid advice: Antiretroviral therapy for HIV infection in adults and adolescents 2009, , , http://www.who.int/hiv/pub/arv/rapid_advice_art.pdf, World Health Organization.
8. Lodwick RK, Sabin CA, Porter K, et al. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study. Lancet 2010, 376(9738):340-345. 3085917, 20638118.
9. Brinkhof MWG, Boulle A, Weigel R, et al. Mortality of HIV-Infected Patients Starting Antiretroviral Therapy in Sub-Saharan Africa: Comparison with HIV-Unrelated Mortality. PLoS Med 2009, 6(4):e1000066. 10.1371/journal.pmed.1000066, 2667633, 19399157.
10. Hosegood V, Vanneste AM, Timaeus IM. Levels and causes of adult mortality in rural South Africa: the impact of AIDS. AIDS 2004, 18(4):663-671. 10.1097/00002030-200403050-00011, 15090772.
11. Mermin J, Were W, Ekwaru JP, et al. Mortality in HIV-infected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort study. Lancet 2008, 371(9614):752-759. 10.1016/S0140-6736(08)60345-1, 18313504.
12. Mwachari CW, Shepherd BE, Cleopa O, Odhiambo JA, Cohen CR. Mortality and burden of disease in a cohort of HIV-seropositive adults in Nairobi, Kenya. Int J STD AIDS 2004, 15(2):120-126. 10.1258/095646204322764325, 15006075.
13. Senkoro KP, Boerma JT, Klokke AH, et al. HIV incidence and HIV-associated mortality in a cohort of factory workers and their spouses in Tanzania, 1991 through 1996. J Acquir Immune Defic Syndr 2000, 23(2):194-202.
14. Urassa M, Boerma JT, Isingo R, et al. The impact of HIV/AIDS on mortality and household mobility in rural Tanzania. AIDS 2001, 15(15):2017-2023. 10.1097/00002030-200110190-00015, 11600831.
15. Welaga P, Hosegood V, Weiner R, Hill C, Herbst K, Newell ML. Coming home to die? The association between migration and mortality in rural South Africa. BMC Public Health 2009, 9:193. 10.1186/1471-2458-9-193, 2706824, 19538717.
16. Hansen AB, Gerstoft J, Kronborg G, Pedersen C, Sorensen HT, Obel N. Mortality in siblings of patients coinfected with HIV and hepatitis C virus. J Infect Dis 2007, 195(2):230-235. 10.1086/510246, 17191168.
17. Celum C, Wald A, Lingappa JR, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010, 362(5):427-439. 10.1056/NEJMoa0904849, 2838503, 20089951.
18. Lingappa JR, Baeten JM, Wald A, et al. Daily aciclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet 2010, 375(9717):824-833. 10.1016/S0140-6736(09)62038-9, 2877592, 20153888.
19. Lingappa JR, Kahle E, Mugo N, et al. Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. PLoS One 2009, 4(4):e5272. 10.1371/journal.pone.0005272, 2671170, 19404392.
20. Lingappa JR, Lambdin B, Bukusi EA, et al. Regional Differences in Prevalence of HIV-1 Discordance in Africa and Enrollment of HIV-1 Discordant Couples into an HIV-1 Prevention Trial. PLoS One 2008, 3(1):e1411. 10.1371/journal.pone.0001411, 2156103, 18183292.
21. Diggle PJ, Heagerty PJ, Liang KY, Zeger SL. Analysis of Longitudinal Data 2002, Oxford University Press, Oxford.
22. Lehmann EL, Casella G. Theory of Point Estimation 1998, Springer, New York, 2.
23. The Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration ACCA-C Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006, 367(9513):817-824. The Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration ACCA-C.
24. Hak E, Verheij TJ, Grobbee DE, Nichol KL, Hoes AW. Confounding by indication in non-experimental evaluation of vaccine effectiveness: the example of prevention of influenza complications. J Epidemiol Community Health 2002, 56(12):951-955. 10.1136/jech.56.12.951, 1756997, 12461118.
25. Muller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 2010, 10(4):251-261. 10.1016/S1473-3099(10)70026-8, 20334848.
26. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997, 126(12):946-954.
27. HIV Surrogate Marker Collaborative Group Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: a meta-analysis. AIDS Res Hum Retroviruses 2000, 16(12):1123-1133. HIV Surrogate Marker Collaborative Group.
28. The Mochudi Prevention Project ART Protocol ClinicalTrials.gov 2012, , , Accessed 30 Aug http://www.clinicaltrials.gov/ct2/show/NCT01583439?term=mochudi&rank=1, The Mochudi Prevention Project ART Protocol.
29. Quinn TC, Wawer MJ, Sewankambo N, , et al. Rakai Project Study Group Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000, 342(13):921-929. 10.1056/NEJM200003303421303, 10738050, Rakai Project Study Group.
30. Lingappa JR, Hughes JP, Wang RS, et al. Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One 2010, 5(9):e12598. 10.1371/journal.pone.0012598, 2938354, 20856886.
31. Jewkes R, Levin J, Penn-Kekana L. Risk factors for domestic violence: findings from a South African cross-sectional study. Soc Sci Med 2002, 55(9):1603-1617. 10.1016/S0277-9536(01)00294-5, 12297246.
32. Braitstein P, Boulle A, Nash D, et al. Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration. J Womens Health (Larchmt) 2008, 17(1):47-55.
33. Mills EJ, Bakanda C, Birungi J, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med 2011, 155(4):209-216.
34. Hanrahan CF, Golub JE, Mohapi L, et al. Body mass index and risk of tuberculosis and death. AIDS 2010, 24(10):1501-1508. 10.1097/QAD.0b013e32833a2a4a, 3063388, 20505496.
35. Madhavan S, Schatz E, Clark B. Effect of HIV/AIDS-related mortality on household dependency ratios in rural South Africa, 2000-2005. Popul Stud (Camb) 2009, 63(1):37-51.
36. Tsai AC, Chopra M, Pronyk PM, Martinson NA. Socioeconomic disparities in access to HIV/AIDS treatment programs in resource-limited settings. AIDS Care 2009, 21(1):59-63. 10.1080/09540120802068811, 18780194.